Health economic evaluation of the use of drug-eluting stents

摘要: The purpose of the economic evaluation German Drug-Eluting Stent (DES) registry includes investigation impact and cost-effectiveness DES compared to bare-metal stents (BMS) between paclitaxel-eluting (PES) sirolimus-eluting (SES). Here, methodology initial results are presented. Patients were recruited in 2005 2006 87 centres across Germany. Selection PES, SES, or BMS was made at discretion cardiologists charge. Clinical, economic, quality life (QoL) data collected baseline up 12 months. Group comparisons conducted using Fisher’s exact t test. Overall, 3,930 patients enrolled: 3,471 (75% male, 65 ± 11 years) received 458 (74% 67 ± 11 years) BMS. Among patients, 1,821 PES 65 ± 10 years) 1,600 SES (76% 65 ± 11 years). There differences clinical procedural characteristics but not QoL. During hospital stay, major adverse cardiac cerebrovascular events occurred 1.6% (PES 1.9%, 1.1%) 2.2% (BMS vs. DES, p = 0.327, 0.706, 0.098, respectively). Hospital treatment costs 4,989 ± 1,284 € 3,609 ± 924 €, respectively, (p < 0.001) with no significant difference SES. large demonstrates increased hospitalisation associated Further analysis will provide estimates on “real world” patient populations for decision makers aid reimbursement decisions within other health care systems.